Antonio Capolongo
Overview
Explore the profile of Antonio Capolongo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cesaro A, Acerbo V, Scialla F, Golia E, Concilio C, Scherillo G, et al.
High Blood Press Cardiovasc Prev
. 2025 Feb;
32(2):199-208.
PMID: 39969794
Introduction: Accurate risk assessment is critical in cardiovascular (CV) prevention, yet physicians often underestimate CV risk, leading to inadequate preventive measures. Aim: This study evaluates the concordance between physician-perceived CV...
2.
Cesaro A, Acerbo V, Scialla F, Scherillo G, De Michele G, Panico D, et al.
Nutr Metab Cardiovasc Dis
. 2025 Feb;
:103843.
PMID: 39934048
Background And Aims: Lipoprotein(a) [Lp(a)] emerging as a significant risk factor for coronary artery disease (CAD). However, the role and the impact of Lp(a) in the early formation and progression...
3.
de Sio V, Gragnano F, Capolongo A, Guarnaccia N, Maddaluna P, Acerbo V, et al.
Int J Cardiol
. 2025 Jan;
423:133028.
PMID: 39890028
Aims: Semaglutide has been shown to reduce cardiovascular events in non-diabetic patients with preexisting cardiovascular disease and overweight/obesity in the SELECT trial. Data on the applicability of these results to...
4.
de Sio V, Gragnano F, Capolongo A, Terracciano F, Maddaluna P, Guarnaccia N, et al.
Int J Cardiol
. 2024 Dec;
422:132921.
PMID: 39708905
With the increasing use of cardiac electronic implantable devices in recent years, the identification of asymptomatic atrial arrhythmias, including atrial high-rate episodes (AHREs) and device-detected subclinical atrial fibrillation (SCAF), has...
5.
Benenati S, Gragnano F, Scalamera R, de Sio V, Capolongo A, Cesaro A, et al.
Int J Cardiol
. 2024 Sep;
417():132568.
PMID: 39284439
Background: Tools for precise prediction of bleeding risk in patients undergoing percutaneous coronary intervention (PCI) with cangrelor are lacking. Methods: Consecutive patients undergoing PCI and treated with cangrelor in 7...
6.
Gragnano F, Capolongo A, Galli M, Calabro P
Eur Heart J Cardiovasc Pharmacother
. 2024 Sep;
10(7):575-577.
PMID: 39257276
No abstract available.
7.
Gragnano F, Capolongo A, Micari A, Costa F, Garcia-Ruiz V, de Sio V, et al.
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202105
The antithrombotic management of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) poses numerous challenges. Triple antithrombotic therapy (TAT), which combines dual antiplatelet therapy (DAPT) with oral anticoagulation...
8.
Gragnano F, Capolongo A, Calabro P
Curr Vasc Pharmacol
. 2023 Nov;
22(1):1-4.
PMID: 38018206
No abstract available.
9.
De-escalation strategies in patients with acute coronary syndrome: a step towards precision medicine
Gragnano F, Capolongo A, Terracciano F, de Sio V, Maddaluna P, Fimiani F, et al.
Expert Rev Cardiovasc Ther
. 2023 Jun;
21(7):545-551.
PMID: 37267100
Introduction: Dual antiplatelet therapy (DAPT) with aspirin and a P2Y inhibitor is a cornerstone in the treatment of patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). Current...
10.
Russo V, Capolongo A, Bottino R, Carbone A, Palladino A, Liccardo B, et al.
J Clin Med
. 2023 Mar;
12(5).
PMID: 36902735
Myotonic dystrophy type 1 (DM1) is the most common muscular dystrophy in adults. Cardiac involvement is reported in 80% of cases and includes conduction disturbances, arrhythmias, subclinical diastolic and systolic...